Related Experiment Video
Updated: Jul 22, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Delayed encephalopathy after COVID-19: A case series of six patients
Takayoshi Akimoto1, Makoto Hara1, Kenta Tasaki1
1Division of Neurology, Department of Medicine, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
Insights
Delayed encephalopathy (DE) following COVID-19 can occur weeks after infection, presenting with neurological symptoms and tremor. Blood-brain barrier dysfunction may play a role in its development.
Area of Science:
- Neurology
- Infectious Diseases
- Neuroimmunology
Background:
- Acute encephalopathy is a severe neurological complication of coronavirus disease 2019 (COVID-19).
- Most cases of acute encephalopathy associated with COVID-19 occur within several weeks of COVID-19 onset.
- This study describes a case series of 6 patients who developed delayed encephalopathy (DE) after COVID-19.
Observation:
- Six patients (2 female, 4 male; ages 65-83) were hospitalized for delayed encephalopathy 34-67 days post-COVID-19 onset.
- Symptoms included altered consciousness, tremor, abnormal behavior, hemiplegia, aphasia, or apraxia, without pneumonitis exacerbation.
- Electroencephalogram showed diffuse slowing, and cerebrospinal fluid analysis revealed elevated protein and blood-brain barrier dysfunction.
Findings:
- All patients recovered consciousness within days, irrespective of immunotherapy.
- Postural tremor persisted for 2 weeks to 7 months in all patients.
- No severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in cerebrospinal fluid, and neuronal autoantibodies were absent.
Implications:
- Delayed encephalopathy after COVID-19 presents with acute encephalopathy and tremor, typically after the fourth week of infection.
- Blood-brain barrier dysfunction is implicated in the pathogenesis of delayed encephalopathy post-COVID-19.
- Further research is needed to elucidate the mechanisms and optimal management of this neurological complication.
Rationale:
Acute encephalopathy is a severe neurological complication of coronavirus disease 2019 (COVID-19). Most cases of acute encephalopathy associated with COVID-19 occur within several weeks of COVID-19 onset. We describe a case series of 6 patients who developed delayed encephalopathy (DE) after COVID-19.
Patient Concerns And Diagnoses:
We evaluated patients who recovered from COVID-19 and showed acute disturbance of consciousness or focal neurological deficits without recurrence of pneumonitis. Six patients, 2 females and 4 males, with ages ranging from 65 to 83 years were included. Durations of hospitalization due to COVID-19 were between 25 and 44 days. The severity of COVID-19 was moderate in 5 and severe in 1 patient. Patients were rehospitalized for acute disturbance of consciousness concomitant with postural tremor and, abnormal behavior, hemiplegia, aphasia, or apraxia between 34 and 67 days after the onset of COVID-19. Chest computed tomography showed no exacerbation of pneumonitis. Brain magnetic resonance imaging showed no specific findings except in 1 patient with an acute lacunar infarction. Electroencephalogram demonstrated diffuse slowing in all patients. Repeat electroencephalogram after recovery from encephalopathy demonstrated normal in all patients. One of the 6 patients had cerebrospinal fluid (CSF) pleocytosis. CSF protein levels were elevated in all patients, ranging from 51 to 115 mg/dL. CSF interleukin-6 levels ranged from 2.9 to 10.9 pg/mL. The immunoglobulin index was 0.39 to 0.44. Qlim(alb) < QAlb indicating dysfunction of the blood-brain barrier was observed in all patients. Severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction of CSF was negative in all patients. Neuronal autoantibodies were absent in serum and CSF.
Interventions And Outcomes:
Immunotherapy including steroid pulses was administered to 3 patients; however, symptoms of encephalopathy resolved within several days in all patients, regardless of treatment with immunotherapy, and their consciousness levels were recovered fully. Notably, postural tremor remained for 2 weeks to 7 months.
Lessons:
In our patients, DE after COVID-19 was characterized by symptoms of acute encephalopathy accompanied with tremor in the absence of worsening pneumonitis after the fourth week of COVID-19 onset. Our findings indicate blood-brain barrier dysfunction may contribute to the pathogenesis of DE after COVID-19.
Related Concept Videos
Viral Meningitis
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy

